Literature DB >> 7889952

Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.

A Barry1, P Fuchs, F Tenover, S Allen, D Hardy, J Jorgensen, J McLaughlin, L Reller.   

Abstract

To confirm preliminary interpretive breakpoints for prototype 5 micrograms levofloxacin disks, 490 strains were tested in vitro using commercially manufactured disks. For in vitro susceptibility testing, 5 micrograms levofloxacin disks can be used with interpretive criteria of < or = 12 mm for resistant (MIC > or = 8.0 micrograms/ml) and > or = 16 mm for susceptible (MIC < or = 2.0 micrograms/ml). Proposed quality control limits for tests of levofloxacin are as follows: Escherichia coli ATCC 25922, zones 29-37 mm or MIC 0.008-0.03 microgram/ml; Pseudomonas aeruginosa ATCC 27853, zones 19-26 mm or MIC 0.5-2.0 micrograms/ml; Staphylococcus aureus ATCC 25923, zones 24-31 mm; Staphylococcus aureus ATCC 29213, MIC 0.06-0.25 microgram/ml and Enterococcus faecalis ATCC 29212, MIC 0.25-2.0 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889952     DOI: 10.1007/bf02111343

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

3.  In vitro activity of S-ofloxacin.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  In vitro activity of l-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci.

Authors:  B Foleno; K P Fu
Journal:  Diagn Microbiol Infect Dis       Date:  1992-08       Impact factor: 2.803

5.  Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.

Authors:  M A Pfaller; A L Barry; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

6.  Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; T L Gavan
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

7.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

  7 in total
  1 in total

1.  Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.